Cancer immunotherapy in 2017: The breakthrough of the microbiota

Nature Reviews Immunology

Volumn 18, Issue 2, 2018, Pages 87-88

  Kroemer, Guido ^a,b,c,d,e,f   Zitvogel, Laurence ^g  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTIDINE DEAMINASE; GEMCITABINE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR MARKER;

AKKERMANSIA MUCINIPHILA; ANTIBIOTIC THERAPY; AUTOPHAGY; BACTEROIDES; BIFIDOBACTERIUM LONGUM; BIOINFORMATICS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; COLLINSELLA AEROFACIENS; COLORECTAL CANCER; ENTEROCOCCUS FAECIUM; EUBACTERIUM LIMOSUM; FUSOBACTERIUM; HUMAN; IN VIVO STUDY; INTESTINE FLORA; MELANOMA; METAGENOMICS; NON SMALL CELL LUNG CANCER; NONHUMAN; PANCREAS ADENOCARCINOMA; PHENOTYPE; PREVOTELLA; PRIORITY JOURNAL; RENAL CELL CARCINOMA; RUMINOCOCCACEAE; SELENOMONAS; SHORT SURVEY; VERRUCOMICROBIA; ANIMAL; BIOLOGICAL MODEL; FECAL MICROBIOTA TRANSPLANTATION; IMMUNOLOGY; IMMUNOTHERAPY; MICROBIOLOGY; MOUSE; NEOPLASM; PROCEDURES; PROGNOSIS; TRENDS;

ANIMALS; BIOMARKERS, TUMOR; FECAL MICROBIOTA TRANSPLANTATION; GASTROINTESTINAL MICROBIOME; HUMANS; IMMUNOTHERAPY; MICE; MODELS, IMMUNOLOGICAL; NEOPLASMS; PROGNOSIS;

EID: 85041317455     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri.2018.4     Document Type: Short Survey

References (11)

1. Geva-Zatorsky, N. et al. Mining the human gut microbiota for immunomodulatory organisms. Cell 168, 928-943 (2017).
2. Haber, A. L. et al. A single-cell survey of the small intestinal epithelium. Nature 551, 333-339 (2017).
3. Bullman, S. et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 358, 1443-1448 (2017).
4. Yu, T. et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 170, 548-563 (2017).
5. Geller, L. T. et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357, 1156-1160 (2017).
6. Peled, J. U. et al. Intestinal microbiota and relapse after hematopoietic-cell transplantation. J. Clin. Oncol. 35, 1650-1659 (2017).
7. Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91-97 (2018).
8. Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97-103 (2018).
9. Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104-108 (2018).
10. Zitvogel, L. et al. Anticancer effects of the microbiome and its products. Nat. Rev. Microbiol. 15, 465-478 (2017).
11. Balachandran, V. P. et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551, 512-516 (2017).